



April 1, 2015

Dawson James Securities Transaction Analysis

Great Basin Scientific, Inc.

Dawson James Securities, Inc. acted as the sole book runner on Feb. 25, 2015 for a follow-on offering for Great Basin Scientific, Inc. (GBSN), a molecular diagnostics company. Great Basin commercializes breakthrough technologies that improve ease-of-use and deliver better cost per result for sample-to-result molecular diagnostic testing. At the time of the offering, GBSN was trading at \$2.55 with a market cap of approx. \$15M and Avg. 3M Vol. was 40k shares.

Through Dawson James' proprietary Diversified Investor Offering utilizing both fundamental institutional investors along with its significant base of high net worth retail and family office investors, close to \$24M was raised in a "best efforts" offering of up to 2,724,000 units at \$8.80 per unit. Each unit consists of one share of Series E preferred stock and eight Series C warrants. Each share of Series E preferred stock will be convertible into four shares of common stock and each Series C warrant will be exercisable into one share of common stock at an exercise price of \$2.55 per share. The units will automatically separate into the Series E preferred stock and Series C warrants on August 25, 2015, provided that the units will separate earlier if at any time after March 27, 2015 the closing price of Great Basin's common stock is greater than \$4.00 per share for 20 consecutive trading days. The units are listed on Nasdaq under the ticker symbol "GBSNU".

This unique structure allowed Great Basin to raise ample working capital to execute their extensive customer rollout as well as to bring two additional diagnostic tests to market. The 6 month "lock up" of the unit allows the company to meet specific milestones and increase both liquidity and market cap. The Company has since announced a strong quarter and hosted a conference call updating investors on their progress and has received a significant patent award. GBSN is trading today at \$5.14, up 101% from the offering. GBSNU is trading at \$14.75 up 67%. Avg. 3M Vol. since the offering has increased to 255k shares.

Dawson James Securities specializes in raising capital for small and microcap growth companies primarily in the Life Science/Health care sector and is a full service investment banking firm with research, institutional and retail sales, execution trading and corporate services. For more information please contact:

Elise Stern, Managing Director, Corporate Finance

estern@dawsonjames.com

561-208-2926

http://www.sec.gov/Archives/edgar/data/1512138/000091228215000084/gb_424b3-03052015.htm

Statements in this announcement regarding GBSU's business which are not historical facts are "forward looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward looking statements, see "Risk Factors" in the Company's S1 (attached).